Huma Therapeutics, a UK-based developer of remote patient monitoring technology, closed a series C round co-led by subsidiaries of chemical and pharmaceutical producer Bayer and electronics manufacturer Hitachi sized at approximately $130m yesterday.
Leaps by Bayer and Hitachi Ventures were joined by electronics providers Samsung and Sony as well as consumer goods producer Unilever, which invested through Samsung Next, Sony Innovation Fund by IGV and Unilever Ventures respectively.
Asset manager HAT’s Technology & Innovation Fund also took part in the round along with private investors Nikesh Arora and Michael Diekmann. Huma has secured an additional $70m commitment that can be accessed at a later date to expand the round to $200m and take its valuation past $1bn, according to CNBC.
Goldman Sachs International was lead placement agent for the deal while HSBC Bank and Nomura were joint placement agents. Nomura has acquired an equity stake in Huma as a part of the transaction.
Formerly known as Medopad, Huma has built a remote patient monitoring platform which records healthcare data through a dedicated mobile app. The data is shared with healthcare organisations and professionals to help increase the efficiency of care and clinical research.
The capital injection will enable the company to expand access to its platform in the US, Asia and the Middle East. It had previously received $25m in a series B round in late 2019 that was led by Bayer, which invested with infrastructure and services conglomerate NWS Holdings and VC firm Healthbox.
NSW Holdings had led Huma’s $28m series A round the year before, participating alongside unspecified family offices and institutional investors. Bayer and Healthbox were identified by TechCrunch as existing investors at the time of the series B round.